MedPath

Prevention of Hypergranulation Tissue After Gastrostomy Tube Placement

Not Applicable
Completed
Conditions
Soft Tissue Inflammation
Interventions
Procedure: Standard Hydrocolloid Dressing
Procedure: Silver Hydrocolloid Dressing
Registration Number
NCT01501539
Lead Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Brief Summary

The primary objective of this study is to compare the incidence of postoperative hypergranulation tissue formation after gastrostomy tube placement among children randomized to one of three treatments, in addition to measuring tube dislodgements and rates of resource utilization for complications.

Detailed Description

Hypergranulation tissue is one of the major immediate complications of gastronomy tube placement. This study aims to determine if using a foam dressing upon placement will prevent its formation, as it has been demonstrated as an effective treatment in healing hypergranulation tissue formation post-operatively. Study participants will be randomized into one of three treatments after gastronomy tube placement (1) standard care, (2) plain foam treatment or (3) silver foam dressing. These treatments will be applied for 30 days post-operatively in addition to standard care of cleaning the gastronomy site daily with soap and water, if assigned to foam intervention. All study materials are free for duration of 30 day intervention and participation will not interfere with routine post-operative care of gastronomy tube site. The total duration of trial will be 6 months and will not require additional study visits outside of routine care. The rate of G-tube dislodgements and associated outcomes will also be measured during the trial.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
171
Inclusion Criteria
  • Children between 1 month and 17 years of age who undergo gastrostomy tube placement by a member of the pediatric surgery faculty at Children's Memorial Hospital will be eligible for inclusion in this study.
Exclusion Criteria
  • Children undergoing gastrostomy tube placement by gastroenterology or interventional radiology at Children's Memorial Hospital.
  • Mother or caregiver of the patient is currently pregnant, breastfeeding and/or planning on getting pregnant within the next 60 days (silver HD has not been studied in pregnant or breastfeeding women)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Standard hydrocolloid dressingStandard Hydrocolloid DressingAt the completion of the operative procedure for gastrostomy tube placement, the surgical incisions will be covered with dermabond, steristrips, and/or tegaderm dressings, according to the surgeons preference. The gastrostomy tube will have a thin layer of hydrocolloid dressing (HD) placed around the gastrostomy tube. The HD will be changed once every other day fo the first 30 days after gastrostomy tube placement. After 30 days, care will revert to standard care.
Silver hydrocolloid dressingSilver Hydrocolloid DressingAt the completion of the operative procedure for gastrostomy tube placement, the surgical incisions will be covered with dermabond, steristrips, and/or tegaderm dressings, according to surgeon preference. The gastrostomy tube will have a thin layer of silver hydrocolloid dressing (HD) placed around the gastrostomy tube. The silver HD will be changed once every other day for the first 30 days after gastrostomy tube placement. After 30 days, care will revert to standard care.
Primary Outcome Measures
NameTimeMethod
The primary outcome is to measure change in Hypergranulation tissue formation around Gastrostomy tube.2 time points: 2 weeks and 6 months post insertion.
Secondary Outcome Measures
NameTimeMethod
The secondary outcome is to measure change in visual assessment of postoperative condition of gastrostomy tube insertion site.2 timepoints: 2 weeks and 6 months post insertion.

Trial Locations

Locations (1)

Children's Memorial Hospital

🇺🇸

Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath